The North Central Cancer Treatment Group (NCCTG) is a multidisciplinary clinical trials organization with the Research Base headquarters located at the Mayo Clinic Cancer Center (MCCC) in Rochester, Minnesota, and membership composed largely of community oncology practices distributed throughout the United States. Since most cancer care in the United States is provided in the community, NCCTG posits that clinical cancer research, conducted in partnership with community practices, provides answers that most accurately reflect outcomes relevant to patient care.
The specific aims of NCCTG are: 1) to improve the duration and quality of life of patients with cancer, 2) to improve understanding of the biology of cancer and the biological consequences of treatment, 3) to improve methods for conducting clinical trials, and 4) to provide an infrastructure for the conduct of cancer control research.
These aims are carried out through the efforts of four Disease Committees: Breast Cancer, Gastrointestinal Cancer, Lung Cancer, and Neuro-oncology; three Modality Committees: Surgery, Radiation Oncology, and Pathology;three Discipline-oriented Scientific Committees: Novel Therapeutics, Quality of Life, and Cancer Control;and five Core Function Committees: Audit, Oncology Nursing Board, Clinical Research Associate Board, Cancer Health Disparities, and Patient Advocate. The research activities of these committees are supported by the Statistics and Data Center and by the Operations Center, both in partnership with the MCCC. NCCTG investigators have contributed substantially to treatment advances for cancer patients in the past grant cycle by demonstrating the superiority of oxaliplatin-based treatment regimens in advanced colorectal cancer and the combination of trastuzumab with adjuvant chemotherapy for patients with loco-regional breast cancer overexpressing the HER-2 protein. We have advanced knowledge of the treatment of patients with brain tumors, especially low-grade glioma, and genetic determinants of outcome in both low- and high-grade glioma, and have identified both successful and unsuccessful cytotoxic, targeted, and radiotherapeutic approaches in patients with breast, lung, colon, pancreatic and esophageal cancers, glioma, hepatoma, lymphoma, and melanoma. We have verified the safety and efficacy of laparoscopic. surgery for patients with colon cancer and for combined surgery and chemotherapy for patients with colorectal cancer metastatic to liver. We have identified the prognostic and predictive value of pharmacogenetic and tumor tissue genetic markers in patients with specific cancers, and have evaluated the validity of surrogate endpoints for carefully defined patient groups. Collectively, these achievements demonstrate the scientific value of NCCTG and provide evidence that NCCTG will continue to contribute meaningful scientific advances in the next grant cycle, as proposed within this grant application.
|Park, Haeseong; Qin, Rui; Smith, Thomas J et al. (2015) North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. Menopause 22:627-32|
|An, Ming-Wen; Mandrekar, Sumithra J; Edelman, Martin J et al. (2014) Exploring the statistical and clinical impact of two interim analyses on the Phase II design with option for direct assignment. Contemp Clin Trials 38:157-62|
|Yoon, Harry H; Tougeron, David; Shi, Qian et al. (2014) KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res 20:3033-43|
|Van Loon, Katherine; Espinoza, Anne M; Fogelman, David R et al. (2014) Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas 43:343-9|
|Cairncross, J Gregory; Wang, Meihua; Jenkins, Robert B et al. (2014) Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol 32:783-90|
|Huang, Jocelin; Nair, Suresh G; Mahoney, Michelle R et al. (2014) Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147. Clin Colorectal Cancer 13:100-9|
|Dy, Grace K; Molina, Julian R; Qi, Yingwei et al. (2014) NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance status. J Thorac Oncol 9:1146-53|
|Kernstine, Kemp H; Moon, James; Kraut, Michael J et al. (2014) Trimodality therapy for superior sulcus non-small cell lung cancer: Southwest Oncology Group-Intergroup Trial S0220. Ann Thorac Surg 98:402-10|
|Cheng, H; Ballman, K; Vassilakopoulou, M et al. (2014) EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial. Br J Cancer 111:1065-71|
|Dueck, Amylou C; Reinholz, Monica M; Geiger, Xochiquetzal J et al. (2013) Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831. Clin Cancer Res 19:5798-807|
Showing the most recent 10 out of 525 publications